Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIVV020 in Cold Agglutinin Disease
NCT04269551Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jun 2020
- Primary completion
- Jan 2022
- Modality
- IgG Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of riliprubart in cold agglutinin disease (CAD), sponsored by Sanofi. Primary endpoint: Adverse Events. Started Jun 2020; status: completed.
02
Drugs
riliprubart
03
Conditions
cold agglutinin disease (CAD)
Beyond the preview
Go deeper on NCT04269551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04269551.